Nektar Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud Amid Trial Irregularities

Overview of the Lawsuit Against Nektar Therapeutics

On April 23, 2026, SueWallSt announced that a securities class action has been initiated against Nektar Therapeutics (NASDAQ: NKTR). Investors who bought shares between February 26, 2025, and December 15, 2025, and experienced losses may be eligible to participate in this lawsuit. The suit arises from serious allegations regarding the company’s handling of clinical trials and the information disclosed to investors.

The Decline in Stock Value

The trouble began on December 16, 2025, when Nektar disclosed that four ineligible patients had been enrolled in its key clinical trial, known as the REZOLVE-AA Phase 2b trial. This admission caused a significant drop in Nektar's stock value, falling by $4.14 per share, or 7.77%, to close at $49.16. The company’s failure to maintain stringent enrollment criteria raised serious questions about its trial processes and transparency with shareholders.

Allegations of Concealment

Throughout the class period, Nektar’s senior management is accused of repeatedly assuring investors that the trial's enrollment adhered to strict protocols and eligibility standards. These assurances were given in various earnings calls, SEC filings, and press releases from February to November 2025. The lawsuit contends that the company's executives were aware of serious enrollment violations long before disclosing them to the public. This gap between internal knowledge and public statements is at the heart of the allegations.

Specific Violations

The complaint highlights several critical protocol violations:
1. Two patients were diagnosed with unstable alopecia areata shortly before randomization, a factor known to be an exclusion criterion.
2. Two additional patients began treatment before completing an eight-week washout period from prior treatments, violating the trial's own stipulated guidelines.

These violations reportedly occurred at trial sites that Nektar claimed were optimized to minimize operational risks. Furthermore, the company's executives had financial incentives tied to maintaining enrollment schedules, which allegedly put pressure on them to overlook these critical enrollment deficiencies.

Financial Context

In July 2025, amidst these troubling developments, Nektar raised $115 million in a public offering. Additionally, during the class period, the CEO sold 46,986 shares of common stock, personally profiting nearly $1 million. These actions have led to further scrutiny regarding the true intentions and ethical responsibilities of the executives at Nektar.

Analyst Insights and Public Reactions

Financial analysts pointed directly to the four ineligible patients as the reason for the stock’s abrupt decline on December 16. Firms such as Piper Sandler, BTIG, and Jefferies have expressed concern over the integrity of Nektar’s statements during the class period. Legal experts, including Joseph E. Levi, Esq., have remarked, "The timeline raises important questions about when certain risks were known internally versus when they were disclosed to the investing public."

Next Steps for Affected Investors

Investors who believe they suffered losses due to these alleged securities fraud violations are urged to take action. Potential lead plaintiffs must submit their information by May 5, 2026. Those interested can contact Joseph E. Levi, Esq. directly for guidance on how to proceed with the class action suit.

Conclusion

This lawsuit represents a significant moment for Nektar Therapeutics and its investors, highlighting the importance of transparent communication in the biotech industry. As the case unfolds, all eyes will be on how the company responds to these allegations and whether they will face further repercussions for their actions. Given the substantial financial stakes involved, affected investors are encouraged to stay informed and consider their legal options as part of this developing story.